1. The Interferon Antagonist Sarcolectin in the Progress of HIV-1 Infection and in AIDS
- Author
-
Ammar Achour, Alain-Jose L. Ilunga, Aboubacar Kaba, Jean-Franç Ois Zagury, and Charles Chany
- Subjects
Protein Conformation ,Immunology ,HIV Infections ,Disease ,Cross Reactions ,Excretion ,Acquired immunodeficiency syndrome (AIDS) ,Interferon ,HIV Seronegativity ,Lectins ,Virology ,HIV Seropositivity ,medicine ,Humans ,Secretion ,Seroconversion ,Acquired Immunodeficiency Syndrome ,Dose-Response Relationship, Drug ,business.industry ,fungi ,Antagonist ,Antibodies, Monoclonal ,Cell Biology ,medicine.disease ,Titer ,Disease Progression ,HIV-1 ,Interferons ,business ,medicine.drug - Abstract
Sarcolectin (SCL) is a nonspecific stimulator of cellular DNA synthesis that was found in all animal sera tested to date. It inhibits the established interferon (IFN)-dependent antiviral state, restoring cells to their normal status. In this study, we examined the excretion/secretion of the IFN antagonist SCL in sera from healthy donors and in sera collected during different periods of human immunodeficiency virus type 1 (HIV-1) infection. We followed HIV-1-infected patients during all stages of development (seroconversion, initial and advanced phases of AIDS) and found a significant increase in SCL in sera of HIV-infected patients compared with seronegative subjects used as controls. This increase was established during seroconversion, and then the titers leveled off. In the final stage of the disease, the SCL titer increased again very significantly. We attribute this rapid rise to the virus-dependent destruction of T cells that can no longer be repaired. The high SCL level observed at this final stage, which is most predictive of the disease’ s progression, suggests that the action, rather than the production, of IFN is impaired.
- Published
- 2002
- Full Text
- View/download PDF